Swagata Yadavar, Indiaspend indiaspend.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from indiaspend.com Daily Mail and Mail on Sunday newspapers.
Elevation Oncology Announces Clinical Cancer Research Publication Highlighting the Specific Inhibition of HER3 by Seribantumab in Preclinical NRG1 Fusion Models
- Results show seribantumab efficiently inhibited HER3 and the entire ERBB family signaling pathway and established a biologically effective dose range for tumors driven by an NRG1 fusion -
- Seribantumab is currently being evaluated in the tumor-agnostic Phase 2 CRESTONE trial for patients with any solid tumor harboring an NRG1 fusion -
News provided by
Share this article
Share this article
NEW YORK, April 6, 2021 /PRNewswire/ Elevation Oncology, a clinical stage biopharmaceutical company focused on the development of precision medicines for patients with genomically defined cancers, announced today the publication in
Press release content from Business Wire. The AP news staff was not involved in its creation.
Bayer to Present New Clinical Data in Indolent non-Hodgkin’s Lymphoma and Additional Research on its Oncology Portfolio at AACR Annual Meeting 2021
April 6, 2021 GMT
WHIPPANY, N.J. (BUSINESS WIRE) Apr 6, 2021
Bayer will present new research across its oncology portfolio at the virtual American Association for Cancer Research (AACR) Annual Meeting 2021, taking place over two weeks on April 10-15 and May 17-21, 2021. The data include an oral presentation in a Clinical Trials Plenary Session on the Phase III randomized, double-blind, placebo-controlled clinical study of the investigational use of Aliqopa ® (copanlisib) in combination with rituximab given intravenously in patients with relapsed indolent non-Hodgkin’s Lymphoma (iNHL) who have relapsed after ≥1 line of treatment, including rituximab (CHRONOS-3).
Abstract Control Number: 3578
Session Type: E-Poster Session
Session Title: Biological Therapeutic Agents
Permanent Abstract Number: 959
Abstract Control Number: 3677
Session Type: E-Poster Session
Session Title: Biological Therapeutic Agents
Permanent Abstract Number: 964
About ST101
ST101 is a peptide inhibitor of C/EBPβ, which is a transcription factor overexpressed in many cancers that regulate cellular differentiation and promote tumor survival and proliferation. ST101 significantly decreases the expression of C/EBPβ target genes/proteins involved in cell survival, proliferation and differentiation including BCL-2, MCL-1, BIRC5/survivin, cyclins and ID family of proteins. ST101 has been demonstrated to induce selective cancer cell cytotoxicity across a variety of tumor types, including but not limited to breast cancer, melanoma, prostate cancer, GBM, lung cancer, and AML. C/EBPβ is expressed and active in cancer cells but not active in normal cells (post-dif
Genprex Inc targets non-small cell lung cancer and diabetes via gene therapy proactiveinvestors.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from proactiveinvestors.com Daily Mail and Mail on Sunday newspapers.